Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

2012554 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 13, Issue 8, pp. 773-781

Field-Weighted Citation Impact: 19.84